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Available online 4 December 2015It is well established that cytotoxic Aβ oligomers are the key factor that triggers the initial tissue and cell modi-
fications eventually culminating in the development of Alzheimer's disease. Aβ1–42 oligomers display a high de-
gree of polymorphism, and several structurally different oligomers have been described. Amongst them, two
types, recently classified as A+ and A−, have been shown to possess similar size but distinct toxic properties,
as a consequence of their biophysical and structural differences. Here, we have investigated by means of single
molecule tracking the oligomer mobility on the plasmamembrane of living neuroblastoma cells and the interac-
tion with the ganglioside GM1, a component of membrane rafts.We have found that A+ and A− oligomers dis-
play a similar lateral diffusion on the plasma membrane of living cells. However, only the toxic A+ oligomers
appear to interact and alter the mobility of GM1. We have also studied the lateral diffusion of each kind of olig-
omers in cells depleted or enriched in GM1. We found that the content of GM1 influences the diffusion of both
types of oligomer, although the effect of the increased levels of GM1 is higher for the A+ type. Interestingly,
the content of GM1 also affects significantly the mobility of GM1 molecules themselves.
© 2015 Elsevier B.V. All rights reserved.Keywords:
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Alzheimer's disease1. Introduction
A plethora of recent results supports the hypothesis that Aβ oligo-
mers are the cytotoxic species mainly responsible for the initial bio-
chemical and functional alterations eventually culminating with the
development of Alzheimer's disease [1]. Accordingly, several therapeu-
tic strategies are now directed at finding antibodies to specifically re-
duce the appearance of Aβ oligomers [2,3]. However, the structure of
Aβ oligomers is not unique, and oligomerswith different conformations
and cytotoxic properties have been described in the past [4–7]. These al-
ternative structures can be obtained in vitrousing different conditions of
aggregation. Recently published results show that Aβ1–42 oligomers of
comparable size but different structure and biophysical properties can
display different toxicities [8]. In this case, the oligomers were classified
as A+ or A−, according to their ability to be recognized by the
conformation-specific antibody A11 [9]. A+ oligomers were found to
be more toxic than A− oligomers, possibly as a consequence of the in-
creased exposure of hydrophobic residues that would destabilize them
and favour their interaction with the plasma membrane.on-linear Spectroscopy (LENS),In general, Aβ1–42 oligomer binding to the plasma membrane ap-
pears to be the preliminary trigger for several downstreammechanisms
of toxicity [10,11]. The ganglioside GM1, a component of membrane
rafts involved in neurodevelopment and neuroprotection, has been
found to interactwith specific types of Aβ1–42 oligomers [11–14], com-
monly referred to as ADDLs (amyloid β-derived diffusible ligands) [15].
Moreover, even a modest depletion of GM1 content can decrease the
degree of interaction of Aβ1–42 oligomers with the plasma membrane
[11]. We have recently shown that distinct Aβ1–42 oligomers recog-
nized by the conformation specific antibody OC and I11, respectively,
diffuse differently on the plasma membrane of living cells [16] and
that Aβ1–42 oligomers alter the mobility of single GM1 molecules
upon binding [12]. Here, we further investigated the GM1/Aβ1–42 rela-
tion by studying the mobility of A+ and A− oligomers on the plasma
membrane of neuronal SH-SY5Y cells by Single Molecule Tracking
(SMT) experiments.
2. Materials and methods
2.1. Preparation and characterization of Aβ1–42 oligomers
Aβ1–42 oligomers were prepared as described previously [8]. In
brief, the lyophilised peptide was dissolved in 100% hexafluoro-2-
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Aβ1–42 oligomers were prepared by suspending the peptide at the
same concentration in 50 mM NaOH and diluting this solution in PBS
to a final Aβ1–42 concentration of 25 μM. Then, the sample was centri-
fuged at 22,000 r.c.f. for 30 min, the pellet discarded and the superna-
tant incubated at 25 °C without agitation for 1 day to obtain A+
oligomers or for 4 days to obtain A− oligomers [8]. Aβ1–42 fibrils
were obtained at a final concentration of 50 μM after 4 days of incuba-
tion. Dot-blot analysis of Aβ1–42 oligomers was performed by spotting
2.0 μl (25 μM) of each conformer onto a polyvinylidene fluoride (PVDF)
membrane. After overnight blocking (1.0% bovine serum albumin in
TBS/TWEEN 0.1%) the blots were probed with A11 (Life Technologies),
OC (Millipore), or 6E10 (Signet) antibodies and then incubated with
the appropriate horseradish peroxidase-conjugated secondary antibod-
ies. The immunolabelled bandswere detected using a SuperSignalWest
Dura (Pierce, Rockford, IL, USA).
2.2. Cell cultures
Human SH-SY5Y neuroblastoma cells (A.T.C.C. Manassas, VA, USA)
were cultured in Dulbecco's Modified Eagle's Medium (DMEM), F-12
Ham with 25 mM HEPES and NaHCO3 (1:1) supplemented with 10%
FBS, 1.0 mM glutamine and 1.0% penicillin and streptomycin solution.
Cell cultures were maintained in a 5.0% CO2 humidified atmosphere at
37 °C and grown until 80% confluence for a maximum of 20 passages.
2.3. Single molecule imaging and tracking
Quantum dot (QD) labelling and live imaging of oligomers and GM1
have been extensively described [12–16]. Briefly, living cells previously
exposed to 10 μMmonomer equivalent of Aβ1–42 A+ and A− oligo-
mers were incubated in phenol red-free Leibovitz's L-15 medium 10%
FBS at 37 °C with anti-Aβ 6E10 (Signet, Dedham, MA) primary antibody
(1:1000) for 20 min. Biotinylated anti-mouse (Jackson Laboratories)
Fab antibodies were used as secondary antibodies at 1:400 dilution for
5 min. Streptavidin-coated QDs (Invitrogen) emitting at 655 nm were
used at 1:10,000 dilution for 1.0 min. For single molecule GM1 experi-
ments, the cells were incubated first with anti-Aβ 6E10 antibody
(1:1000) for 20 min, then for 5 min with anti-mouse Alexa Fluor 488
(Invitrogen, 1:500) and 10 μg/ml biotinylated CTXB, and finally with
streptavidin QDs 655 (1:10,000) in QD binding buffer for 1.0 min. The
cells were monitored with a custom-made wide-field epifluorescence
microscope equipped with an oil-immersion objective (Nikon Plan
Apo TIRF 60x/1.45), a Reliant 150 Select argon ion laser (excitation
line 488 nm) and a heating chamber. The emission filters (Semrock)
were FF499-Di01-25 dichroic, FF01-655/15-25 (for QDs) and FF01-
530/43-25 (for Alexa 488). Movies were acquired with an integration
time of 30 or 100 ms with an Electron Multiplying Charge-Coupled
iXon camera (Andor). Recording sessions did not last more than 30min.
Tracking of single QDs, identified by their fluorescence intermit-
tence, was performed with MATLAB (MathWorks, Natick, MA) using a
homemade macro that accounts for blinking in the fluorescence signal
[17–19]. In brief, the method consisted of two main steps, applied suc-
cessively to each frame of the sequence. First, the fluorescent spots
were detected by cross-correlating the image with a Gaussian model
of the Point Spread Function. A least-squares Gaussian fit was applied
(around the local maximum above a threshold) to determine the centre
of each spot with a spatial accuracy of 10–20 nm (depending on the
signal-to-noise ratio). Second, QD trajectorieswere assembled automat-
ically by linking, frame to frame, the centres of the fluorescent spots
likely coming from the same QD. The association criterion was based
on the assumption of free Brownian diffusion and took into account
short blinking events. After completion of the process, a manual associ-
ation step was performed, in which QD trajectories of maximal length
were assembled from smaller fragments separated by longer blinking
events that were not taken into account by the automatic linkingprocedure. For single molecule tracking experiments, we incubated
the cellswith CTXB for times shorter than for standard immunolabelling
experiments, thus obtaining a lower level of labelling. The concentration
of streptavidin-QDs was largely in excess with respect to biotin-CTXB.
Therefore, most, if not all, of the CTXB molecules bound to the plasma
membrane are expected to be labelled.2.4. Quantitative analysis of the diffusion coefficient
The mean square displacement (MSD) analysis allows for cal-
culating the initial diffusion coefficient (D) of each particle [18,19].
Briefly, physical parameters can be extracted from each trajectory
(x(t),y(t)) by computing theMSD [20], as calculated from the following
formula:
MSD ndtð Þ ¼ 1
N−n
XN−n
i¼1
½ ðX iþnð Þ−XiÞ2 þ y iþnð Þ−yi
 2

where xi and yi are the coordinates of a particle on frame i, dt is the time
between two successive frames,N the total number of frames of the tra-
jectory and ndt the time interval over which the displacement is aver-
aged. This function enables the analysis of the lateral dynamics on
short (initial diffusion coefficient) and long (types of motion) time
scales. Different types of motion can be distinguished from the time de-
pendence of the MSD [20]. The initial diffusion coefficient (D) is deter-
mined by fitting the initial 2 to 5 points of the MSD against time plot
with MSD(t) = 4D2-5 t + b.2.5. Modulation and evaluation of membrane GM1 content
SH-SY5Y cells were seeded on glass coverslips and treated with
25 μM D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
(PDMP; Matreya LLC, Pleasant Gap, PA, USA), an inhibitor of GM1 syn-
thesis, or with 100 μg/ml bovine brain GM1 (Sigma-Aldrich) and incu-
bated for 48 h at 37 °C. Cytotoxicity of PDMP was assessed by the MTT
assay as previously reported [21]. After incubation for 48 h at 37 °C,
the cells were loaded with 2.25 μg/ml CTXB and analysed using a FACS
Canto flow cytometer (Beckton Dickinson Biosciences, San Jose, CA,
USA). The measured fluorescence intensities were expressed as frac-
tional changes above the resting baseline, ΔF/F, where F is the average
baseline fluorescence in control cells with basal GM1 content (taken
as 100%) and ΔF represents the fluorescence changes over the baseline
in PDMP- or GM1-treated cells [13]. The SH-SY5Y cells were also seeded
on glass coverslips and treated with 4.5 μg/ml Alexa Fluor 647-
conjugated CTXB or, alternatively, with 1:100 diluted rabbit polyclonal
anti-GM1 antibodies (Calbiochem, EMD Chemicals Inc., Darmstadt,
Germany) and then with Alexa Fluor 488-conjugated anti-rabbit sec-
ondary antibodies diluted 1:1000. The emitted fluorescencewas detect-
ed after excitation at 647 and 488 nm, respectively, using a confocal
Leica TCS SP5 scanning microscope (Mannheim, Germany) equipped
with an argon laser source. A series of 1.0 μm thick optical sections
(1024 × 1024 pixels) was taken through the cell depth for each sample
using a Leica Plan Apo 63× oil immersion objective and projected as a
single composite image by superimposition.2.6. Statistical analysis
D values are log normally distributed. Statistical significance was
evaluated by ANOVA test performed on the log normal distributions. A
p value b 0.05was considered statistically significant. The data analysed
were obtained from three independent experiments.
Table 1
Diffusion coefficientsa of different Aβ1-42 oligomers on the plasmamembrane of SH-SY5Y
neuroblastoma cellsb.
Oligomers
(primary antibody)
GM1 depleted
Dmedian
(μm2 s−1)
GM1
Basal
Dmedian
(μm2 s−1)
GM1 enriched
Dmedian
(μm2 s−1)
Aβ1–42 A+ (6E10) 1.2 × 10−2 8.7 × 10−3 3.8 × 10−4
Aβ1–42 A− (6E10) 3.3 × 10−2 5.9 × 10−3 3.7 × 10−3
Aβ1–42 ADDLs (DE2B4)c 6.1 × 10−4
Aβ1–42 ADDLs (OC)c 9.4 × 10−4
Aβ1–42 ADDLs (I11)c 4.0 × 10−3
GM1d 1.7 × 10−1 6.7 × 10−2 1.8 × 10−2
a Since the diffusion coefficients are distributed over several orders of magnitude, we re-
port the median value instead of the mean value.
b Cells were incubated with distinct oligomers solutions.
c Data from [15].
d GM1 labelled with biotin-CTXB associated to streptavidin-655QDs.
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3.1. A+ and A−oligomer dynamics on the cell membrane
Wehave investigated themembrane dynamics of A+ andA−Aβ1–
42 oligomers, which have similar size but display different cytotoxicity
[8]. The conformational properties of Aβ1–42 monomer, oligomers
and fibrils were evaluated by immunoblot analysis using antibodies
specific for prefibrillar (A11) and fibrillar (OC) oligomers (Fig. 1a) ac-
cording to Ladiwala et al. [8]. The proper loading of each Aβ1–42 assem-
bly was confirmed by the sequence-specific antibody 6E10, which
recognizes the N terminus of Aβ1–42 (Fig. 1a). The preformed oligo-
mers were incubated with SH-SY5Y human neuroblastoma cells for
20 min and labelled with primary 6E10 antibodies and secondary anti-
bodies coupled to quantum dots (QDs) emitting at 655 nm (Fig. 1b). Al-
though incubated with the cells at the same concentration, the average
number of single-QD-labelled A+ oligomers per cell was two folds
higher thanA−. In order to be confident on the nature of the species ob-
served,we incubated the cells withmonomers and fibrils in place of A+
andA− oligomers.We found thatmonomers andfibrils do not bind sig-
nificantly to the cells under the conditions examined here (see Supple-
mentary Movies 1 and 2). These results suggest that if any dissociation
or fibrillation of oligomers occurs during the incubation time, it is un-
likely to be detected as these species do not bind to the cells (or the
epitope may not be accessible to the antibody in case of themonomer).
We conclude that what we image in our recordings are the oligomeric
species. The majority of individual oligomers of both types appeared
confined, with few following Brownian motion (Fig. 1c,d andFig. 1.Dot-blot analysis and SMT of A+andA−Αβ1–42 oligomers. A) Conformation-specific an
(25 μMmonomer equivalents) and fibrils (F) (50 μMmonomer equivalents) were assembled f
membranes were probed with conformation-specific (A11, prefibrillar oligomers (top), OC, fibr
bodies. B)General surface labelling scheme of Aβ oligomers on the plasmamembrane (PM). The
secondary biotinylated Fab antibodies coupled to streptavidin 655QDs (bFAb/s655QD). B) and
corresponding trajectories extrapolated from the recordings. Scale bar 2 μm.Supplementary Movie 3). Interestingly, A+ and A− oligomers
displayed a median lateral diffusion coefficient comparable to that of
Aβ1–42 ADDL oligomers labelled with the conformational antibody
I11, specific for non-fibrillar species and analogue to the A11 antibody
that recognizes A+ oligomers [9] (Table 1). However, the mobility of
the different types of Aβ oligomers was higher than that observed for
other amyloid aggregates [16]. The faster diffusion was not attributable
simply to the smaller size of these oligomers, as their measured sizes
were comparable (approximately 4–6 nm [8]). In addition, the use of
synthetic giant unilamellar vesicles (GUVs) led us to propose that thetibody analysis of Aβ assembly. The Aβ1–42monomer (M) and theA+andA− oligomers
or 1–4 days (without agitation), and then deposited on PVDF membranes. Afterward, the
illar conformers (middle) and sequence-specific (6E10, N-terminus of Aβ (bottom)) anti-
cells were incubatedwith distinct oligomers solutions and labelledwith primary (Ab) and
C) Example of single A+ oligomers on the plasma membrane of living SH-SY5Y cells and
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their interactionwith cellular structures [16]. Although the subtle differ-
ences in structure between A+ and A− oligomers do not appear to in-
fluence significantly their mobility, they can affect the amount of
oligomers bound to the plasma membrane which, in turn, appears to
be related to the degree of cytotoxicity.3.2. Influence of A+ oligomers on GM1 membrane dynamics
In the light of recent results showing the impact of amyloid oligo-
mers on GM1 dynamics [12–22], we have sought to define conditions
in which A+ and A− oligomers affected the mobility of GM1. Similar
to previous experiments,we labelled the oligomers bound to theplasma
membrane with primary and secondary Alexa488 antibodies (Fig. 2a),
whereas GM1 was labelled with biotinylated-cholera toxin subunit B
(CTXB) and streptavidin-655QDs. Interestingly, we found some GM1
molecules co-localizing with A+ aggregates (Fig. 2b, Supplementary
Movie 4). The mean square displacement (MSD) against time plot re-
vealed that these GM1molecules displayed a limited type ofmotion, in-
stead of the Brownianmotion observed in general (Fig. 2c). On the other
hand, in the case of A− oligomers, we could not find any overlap with
GM1molecules. These results show clearly that the toxic A+ oligomers
interact with GM1. These data further confirm the direct implication of
GM1, a constituent of membrane rafts, in the pathogenic cascade trig-
gered by amyloid oligomers.Fig. 2. SMT of GM1 in the presence of A+ oligomers. A) General surface labelling scheme
of GM1 and Aβ oligomers on the plasma membrane. The cells were incubated with solu-
tions of either oligomer type, which was labelled with primary and secondary Alexa488
antibodies. GM1 was labelled with biotinylated CTXB (bCTXB) coupled to streptavidin
655QDs. B) Example of freely moving (red) or confined (green) single GM1 molecules
on the plasmamembrane of living SH-SY5Y cells. C) Trajectories extrapolated from the re-
cordings in B superimposed to the image of GM1 (red) and A+ oligomers (green).
Scale bar 2.0 μm. D) Plot of MSD against time showing that the different dynamic behav-
iour of the two GM1 molecules in B and in C is dependent on the co-localization with
A+ oligomers.3.3. Influence of GM1 on A+ membrane dynamics
As membrane GM1 binds differently to either type of oligomers and
the latter influence differently GM1 mobility on the cell membrane, we
tested whether and how changes in the GM1 content affected oligomer
mobility. In order to decrease or to increase the amount of GM1 in the
plasma membrane, SH-SY5Y cells were treated with 25 μM D-threo-1-
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhib-
itor of GM1 synthesis, orwith 100 μg/ml bovinebrainGM1, respectively.
Confocal images of cells labelled eitherwith anti-GM1 antibody and sec-
ondary Alexa488 antibody, or CTXB-Alexa647, showed depletion or en-
richment inGM1 after either treatment (Fig. 3a). Quantitative FACS flow
cytometer analysis of CTXB-Alexa647 labelled cells confirmed signifi-
cant changes with respect to the untreated control cells with basal
GM1 content (Fig. 3b). A dose-dependent curve of cell viability showed
the absence of any PDMP cytotoxicity at our experimental conditions
(Fig. 3c).
Initially, we used the so-treated cells to investigate, by SMT, the ef-
fect of altered GM1 content on GM1 dynamics in the membrane, a
study never reported before. The average MSD was calculated from
the trajectories of single GM1molecules labelledwith biotin-CTXB asso-
ciated with streptavidin-655QDs (Fig. 4a, b and Supplementary Movie
5). The linear fitting of the data displayed in the plot of MSD against
time suggested that GM1 molecules display Brownian diffusion under
all the conditions analysed here (Fig. 4c). However, the distribution of
the initial diffusion coefficients (D) extrapolated from the MSD of each
GM1 molecule highlighted significant changes (Fig. 4d). The overlap-
ping of the distributions under different conditions is a general conse-
quence of SMT experiments, whose strength is to show how spread
the measured values are. The diffusion coefficients of a biological mole-
cule obtained by SMT can be distributed over several orders of magni-
tude [19]. With respect to cells at basal conditions, the median D valueFig. 3.Alterations of GM1 content. A) Confocal images of cells incubatedwith 25 μMPDMP
(depleted), or with 100 μg/ml bovine brain GM1 (enriched) for 48 h, or cell culture medi-
um and labelled with anti-GM1 antibody and secondary Alexa488-antibody (green), or
CTXB-Alexa647 (red). B) FACS flow cytometer analysis of CTXB-Alexa647 labelled cells
treated as above. The values are means± s.d. of three independent experiments, (*) indi-
cates significant differences relative to untreated control cells (basal) (p ≤ 0.05). C) Dose-
dependence curve of PDMP cytotoxicity assessed by the MTT assay. Cell viability was
expressed as percent of MTT reduction in treated cells with respect to untreated cells
(taken as 100%).
Fig. 4. The content of GM1 influences its own lateral diffusion. A) SMT of GM1 labelled
with bCTXB coupled to s655QD in cells in basal conditions (grey), or treated with 25 μM
PDMP (red) and 100 μg/ml bovine brain GM1 (blue). Scale bar 5.0 μm. B) Trajectories ex-
trapolated from the recordings in A. C) Average mean square displacement of GM1 mole-
cules (n N 90 for each condition). D) Box plot of diffusion coefficients of single GM1
molecules in cells with basal or modified GM1 content. ANOVA analysis of log normal dis-
tributed data, F statistic = 33.9, p b 0.0001.
Fig. 5. The GM1 content influences the lateral diffusion of A+ and A− oligomers. A) and
B) Box plot of diffusion coefficients of single A+ (n N 90 for each condition) and A− olig-
omers (n N 40 for each condition), respectively, in cells with basal GM1 content (grey)
and in cells treated with 25 μM PDMP (purple) or with 100 μg/ml bovine brain
GM1 (cyan). The oligomers were labelled with primary and secondary bFab antibodies
coupled to s655QDs. ANOVA analysis of log normal distributed data, A+, F statistic =
15.3, p b 0.0001; A−, F statistic = 5.7, p = 0.0046.
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enriched in GM1, respectively (Table 1). These changes in membrane
fluidity in relation to the content of GM1 could affect the interaction
and localization of membrane proteins, and might be of relevance also
when considering the role of GM1 in neurodevelopment and neuropro-
tection [23].
Then, the cells depleted or enriched in GM1 were incubated with
A+ or A− oligomers labelled with 6E10 antibody and 655QDs, as de-
scribed above. ANOVA analysis of the log-normally distributed D values
indicated that the GM1 content significantly affected the dynamic be-
haviour of both types of oligomers (Fig. 5). The effect was particularly
relevant for A+ oligomers in GM1-enriched cells, where the median
D value decreased by over one order of magnitude with respect to
basal conditions.
4. Discussion
Gangliosides, in particular GM1, have been known for a long time to
be involved in neurodegenerative conditions such as Alzheimer's dis-
ease [24,25]. Knowledge gained in the last ten years has clearly depicted
raft GM1 as a main nucleator [14,26–28], interactor and concentrator of
amyloid assemblies, particularly Aβ oligomers [29], which triggers the
early event of amyloid cytotoxicity [30]. In particular, it has been report-
ed that membranes may initiate AD through the formation of toxic Aβ
amyloid fibrils on clustered, not diffused, GM1, which differed from
those grown in solution [31]. These data highlight the importance of
assessing GM1 mobility on the cell membrane to better define
oligomer-membrane interaction and amyloid aggregate cytotoxicity.In addition, Yanagisawa et al. identified a specific form of Aβ bound to
GM1 in brains displaying the early pathological changes associated
with AD suggesting that GM1-bound Aβ could act as a seed for aggre-
gate growth [32]. These studies have contributed to focus the involve-
ment of GM1 in the early events of Aβ aggregation and plaque
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that an increase in GM1 [33] together with altered distribution of GM1
and GM2 [25,34] are found in the brains of AD people in respect to
healthy subjects; moreover, GM1 levels were found to be significantly
increased in amyloid-positive synaptosomes obtained from AD brains
[35], implying a pathological significance of GM1 increase at presynap-
tic neuritic terminals in AD. Therefore, the pivotal role of the aggregate-
GM1 complexes can be true even in the case where raft associated pro-
teins such as PrP have been shown to be affected by such interaction,
which favours the assembly ofmembrane complexes triggering specific
signalling cascades [36,37]. This further confirms the importance of
studying the biophysical features of the Aβ-GM1 interaction and the ef-
fects of the latter on GM1 dynamics in the cell membrane.
Our recent research has shown that membrane lipid content, partic-
ularly where cholesterol and GM1 are concerned, modulates oligomer
affinity to the membrane itself and hence their ability to affect mem-
brane lipid order and permeability [13]. This holds true also for non-
toxic variants of amyloid oligomers, whose different biophysical and
structural properties result in different affinities to the cell membrane
that, in turn, are modulated by membrane lipid content [11]. This has
led us to propose that amyloid oligomer toxicity is not a property strictly
inherent in oligomers but, rather a behaviour that emerges from a com-
plex interplay between the structural and biophysical properties of both
themembrane and the oligomers taken as a whole [38]. These data fur-
ther highlight the importance of membrane GM1 and its clusters as a
key modulator of amyloid cytotoxicity and foster further research to
better elucidate from a biochemical, biological and biophysical perspec-
tive the relationship between oligomers and the cell membrane.
Here we used single molecule tracking experiments to investigate
the effect on oligomermobility of the interactionwith GM1 on the plas-
mamembrane of neuronal cells of two types of amyloid oligomers of the
Aβ1–42 peptide grown at different times (A+ and A−), whose bio-
physical and cytotoxicity properties have been previously described
[8]. In general, the single molecule approach represents a novel and
valuable tool for investigating the biology of Aβ oligomers [39,40]. In
our study, we investigated the type and extent of the mobility of either
oligomer and of GM1 in cultured SH-SY5Y neuroblastoma cells. To do
this, we employed a biophysical approach using both GM1 and oligo-
mers labelled with quantum dot particles that enabled us to monitor
the trajectories of either component and their lateral diffusion on the
cell membrane. By using a similar approach, we have recently shown
that distinct Aβ1–42 oligomers recognized by the conformation specific
antibody OC and I11, respectively, diffuse differently on the plasma
membrane of living cells on the basis of their structural properties
[16] and that the same oligomers alter the mobility of single GM1 mol-
ecules upon binding [12]. Our data indicate that GM1 mobility on the
cell is strongly affected by the interaction with the toxic A+ oligomers
whereas A− oligomers do not interact. However, increasing GM1 con-
tent in the cell membrane matched a considerable reduction of oligo-
mer mobility possibly resulting from GM1 clustering. The increase in
GM1 content might affect the clustering and enlargement of existing
raft platforms, or induce the formation of new ones. Alternatively,
GM1 depletion by cell treatment with PDMP resulted in a significant
increase of GM1 mobility possibly by decreasing platform size or by re-
ducing platform stability. Since PDMP is a broad spectrum ganglioside-
depleting agent, several different gangliosides, apart fromGM1,may ac-
count, at least in part, for the observed increase in GM1 mobility in our
experimental conditions. Such consideration agrees with previous data
on the ability of some gangliosides, such as GM3, to bind Aβ1–42 oligo-
mers [41–44], supporting a minor mechanistic role of other
glycosphingolipids in addition to GM1 in mediating the increase of lat-
eral diffusion of A+ oligomers on neuronal membranes. However the
pivotal role of GM1 is supported by its abundance in neural tissue and
by the data showing that its content gradually increases with age with
parallel decrease of GM3 [45]; moreover, GM1 is increased in the CSF
of AD patients [29]. It has also been found that the glycolipid-bindingdomain of Aβ does not recognize GM3 but GM1; themolecular determi-
nants of the high affinity of such interaction have been reported [46]. Fi-
nally, the Selkoe group failed to detect an enrichment of brain lipids
other than GM1 bound to Aβ in their recent paper supporting their ev-
idence that Aβ oligomers preferentially bind to GM1 [29].
A large wealth of data has convincingly reported the involvement of
membrane GM1 in AD pathogenesis through the promotion of Aβ bind-
ing and misfolding, the nucleation of its toxic aggregates, the recruit-
ment of pre-formed oligomers, as well as the importance of lipid
clusterization in all these events. Accordingly, the use of new biophysi-
cal techniques and approaches to study those events at the cell mem-
brane level can provide useful information to better define the
structural, biophysical and molecular modifications underlying the
first steps of Aβ aggregation into cytotoxic assemblies as well as the en-
suing early biochemical modifications of the involved cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.12.009.
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